Douglas Bonhaus, PhD, is a drug-discovery scientist with more than twenty years of experience in the pharmaceutical industry. Initially trained in pharmacology and toxicology at the University of Arizona, Bonhaus has held leadership positions at Syntex, Roche and ACADIA Pharmaceuticals. He is the cofounder of Denysias Bioscience, a company focused on developing novel therapies for impulse control disorders in patients with Parkinson’s disease, now entering clinical stages. Bonhaus now serves as the President and Chief Executive Officer of Neuropore Therapies.